Global Leading Market Research Publisher QYResearch announces the release of its latest report “Gel Filtration Materials – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Gel Filtration Materials market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Gel Filtration Materials was estimated to be worth US$ 60 million in 2025 and is projected to reach US$ 109 million, growing at a CAGR of 9.0% from 2026 to 2032. Gel Filtration Materials are a porous material used for chromatographic separation, commonly used in gel filtration (also known as molecular sieve) chromatography, to separate molecules according to their size. It is made of polymers or polysaccharide-based materials (such as dextran, polyacrylamide or silica gel) with a certain pore size. Substances with smaller molecules can enter the pores and delay their outflow, while larger molecules are excluded and flow out preferentially, thereby achieving molecular weight separation. It is widely used in protein purification, peptide analysis and research on biomacromolecules. Sales volume in 2024 is expected to be 12,000 liters, with an average price of US$5,000 per liter.
Addressing Core Size-Exclusion Chromatography (SEC), Protein Aggregate Removal, and Biopharmaceutical Purification Pain Points
Biopharmaceutical manufacturers, protein scientists, and academic researchers face persistent challenges: purifying monoclonal antibodies (mAbs), recombinant proteins, and viral vectors requires removal of aggregates (high molecular weight species) and buffer exchange (desalting) with minimal sample dilution. Gel filtration materials (size-exclusion chromatography (SEC) resins) —porous beads (dextran, agarose, polyacrylamide, silica) that separate molecules by hydrodynamic volume—have emerged as the essential polishing step in biopharmaceutical downstream processing. However, product selection is complicated by four distinct base matrix chemistries: dextran-based (Sephadex, low pressure), agarose-based (Superose, Sepharose, high resolution), polyacrylamide-based (Bio-Gel P, high resolution), and others (silica, cellulose, composite). Over the past six months, new continuous bioprocessing adoption, mAb aggregate control regulatory requirements, and gene therapy vector purification have reshaped the competitive landscape.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6095200/gel-filtration-materials
Key Industry Keywords (Embedded Throughout)
- Gel filtration materials
- Molecular sieve chromatography
- Dextran agarose polyacrylamide
- Biopharmaceutical purification
- Protein aggregate removal
Market Landscape & Recent Data (Last 6 Months, Q4 2025–Q1 2026)
The global gel filtration materials market is concentrated among global life sciences and bioprocessing leaders. Key players include Cytiva (US/Sweden, former GE Healthcare Life Sciences), Bio-Rad Laboratories (US), Merck (Germany), Tosoh Bioscience (Japan), Sartorius Stedim Biotech (Germany), Repligen Corporation (US), Yeasen (China), Thermo Fisher Scientific (US), Purolite Life Sciences (US), Avantor (US), Bio-Works Technologies AB (Sweden), Agilent Technologies (US), Phenomenex (US), Changzhou smart-Lifesciences Biotechnology Co., Ltd. (China), and Bioeast (China).
Three recent developments are reshaping demand patterns:
- Continuous bioprocessing adoption: Continuous downstream processing (connected multi-column chromatography) requires high-resolution gel filtration resins for final polishing (aggregate removal). Continuous SEC segment grew 10-12% in 2025.
- mAb aggregate control regulatory requirements: FDA and EMA require aggregate control (high molecular weight species) for mAbs and gene therapies (immunogenicity risk). SEC is standard method for aggregate removal. Regulatory compliance segment grew 8-10% in 2025.
- Gene therapy and viral vector purification: Adeno-associated virus (AAV), lentivirus, and other viral vectors for gene therapy require SEC for empty/full capsid separation and aggregate removal. Gene therapy segment grew 12-15% in 2025.
Technical Deep-Dive: Gel Filtration Material Types
- Dextran-based (Sephadex, cross-linked dextran beads). Advantages: low cost, wide range of fractionation ranges (Sephadex G-10 to G-200), suitable for desalting and buffer exchange (G-10, G-25). A 2025 study from the International Bioprocessing Association found that dextran-based resins account for 25-30% of gel filtration material volume. Disadvantages: lower pressure limit (low pressure chromatography), limited resolution. Accounts for approximately 20-25% of gel filtration materials market volume.
- Agarose-based (Superose, Sepharose, cross-linked agarose). Advantages: high resolution (sharp peaks), high pressure limit (medium to high pressure chromatography), wide fractionation range (10 kDa to 10,000 kDa), and suitable for mAb aggregate analysis and polishing. Accounts for approximately 35-40% of market volume (largest segment), dominating biopharmaceutical mAb purification and analytical SEC.
- Polyacrylamide-based (Bio-Gel P, polyacrylamide beads). Advantages: high resolution, hydrophilic (low non-specific binding), and suitable for peptide and protein analysis (Bio-Gel P-2 to P-100). Accounts for approximately 20-25% of volume, dominating peptide analysis and research applications.
- Others (silica-based, cellulose-based, composite) accounts for 10-15% of volume.
User case example: In November 2025, a biopharmaceutical manufacturer (mAb, 10,000 L bioreactor) published results from using agarose-based gel filtration materials (Cytiva Superdex 200, Tosoh TSKgel G3000SW, Bio-Rad ENrich SEC) for aggregate removal (polishing step). The 12-month study (completed Q1 2026) showed:
- SEC resin: agarose-based (Superdex 200, 10-600 kDa fractionation range).
- Aggregate removal: <1% aggregates (starting 5-10% aggregates) – FDA compliant.
- Resolution: baseline separation of mAb monomer from dimer, trimer, and higher aggregates.
- Yield: 95% (monomer recovery).
- Cost per liter: agarose $8,000 vs. dextran $2,000 (4x premium). Payback period (regulatory compliance + yield): 12 months.
- Decision: Agarose-based for mAb polishing (high resolution); dextran-based for desalting (buffer exchange).
Industry Segmentation: Discrete vs. Continuous Manufacturing
- Gel filtration material manufacturing (bead formation (emulsion polymerization (dextran, polyacrylamide), suspension polymerization (agarose)), cross-linking (epichlorohydrin), sizing, packing) follows batch chemical manufacturing (low volume, high value). Production volumes: thousands of liters of resin annually.
- Pre-packed column manufacturing (resin packed into glass, plastic, or stainless steel columns) is batch discrete.
Exclusive observation: Based on analysis of early 2026 product launches, a new “high-resolution agarose-based SEC resin” (sub-10μm beads) for UPLC and analytical SEC (monomer/aggregate analysis) is emerging. Traditional SEC resins (20-50μm) for preparative purification. Sub-10μm resins (Cytiva Superdex 5/10 Increase, Tosoh TSKgel UP-SW3000, Bio-Rad ENrich SEC) offer 2-3x higher resolution for analytical methods (aggregate quantitation). Sub-10μm resins command 50-100% price premium ($15,000-20,000/L vs. $5,000-10,000/L) and target QC labs and analytical development.
Application Segmentation: Biopharmaceutical Industry, Scientific Research & Academic Laboratories, Others
- Biopharmaceutical Industry (mAb aggregate removal, buffer exchange (desalting), viral vector purification (AAV, lentivirus), final polishing) accounts for 60-65% of gel filtration materials market value (largest segment). Agarose-based dominates. Fastest-growing segment (10-12% CAGR), driven by biopharma growth and aggregate control regulations.
- Scientific Research & Academic Laboratories (protein-protein interaction analysis, protein complex characterization, native molecular weight determination, nucleic acid purification) accounts for 25-30% of value. Dextran-based, agarose-based, and polyacrylamide-based.
- Others (peptide analysis, biomacromolecule research) accounts for 5-10% of value.
Strategic Outlook & Recommendations
The global gel filtration materials market is projected to reach US$ 109 million by 2032, growing at a CAGR of 9.0% from 2026 to 2032.
- Biopharmaceutical manufacturers: Agarose-based SEC resins (Superose, Superdex, TSKgel, ENrich) for mAb aggregate removal (high resolution, regulatory compliance). Dextran-based (Sephadex) for desalting/buffer exchange (lower cost). Sub-10μm resins for analytical SEC (aggregate quantitation, QC labs).
- Academic and research labs: Dextran-based (Sephadex) for desalting; polyacrylamide-based (Bio-Gel P) for peptide analysis; agarose-based for protein complex analysis.
- Gene therapy manufacturers: SEC resins for AAV empty/full capsid separation and aggregate removal.
- Manufacturers (Cytiva, Bio-Rad, Merck, Tosoh, Sartorius, Repligen, Yeasen, Thermo Fisher, Purolite, Avantor, Bio-Works, Agilent, Phenomenex, Changzhou smart-Lifesciences, Bioeast): Invest in sub-10μm high-resolution SEC resins (UPLC analytical), continuous SEC resins (high-flow, multi-column chromatography), and viral vector-specific SEC resins (AAV, lentivirus). Pre-packed, ready-to-use columns for research and process development.
For biopharmaceutical manufacturing (mAbs, gene therapies, biosimilars), gel filtration materials (SEC resins) are essential for aggregate removal, buffer exchange, and final polishing. Agarose-based dominates mAb polishing (high resolution); dextran-based for desalting. Sub-10μm resins emerging for analytical SEC. Biopharmaceutical industry growth and aggregate control regulations drive demand.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
